射频消融治疗非小细胞肺癌患者血清CYFRA21-1变化

CHANGES IN SERUM CYFRA21-1 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PERCUTANEOUS RADIOFREQUENCY HYPERTHERMIA

观察经皮肺穿刺锚状电极高温射频消融治疗48例非小细胞肺癌患者血清CYFRA21-1水平的变化以探讨该治疗方法的近期疗效.采用放射免疫法分别测定射频治疗前1 d、治疗后10、20和30 d患者血清CYFRA21-1水平.结果发现,患者血清CYFRA21-1在治疗前总体表达水平为(14.23±8.07)μg.L-1,鳞癌和腺癌患者分别为(20.48±11.23)和(5.48±3.42)μg.L-1,鳞癌患者显著高于腺癌患者(P<0.01).血清CYFRA21-1水平在射频治疗10 d后无明显变化,20 d始显著下降(P<0.01).表明高温射频治疗非小细胞肺癌近期疗效明显,且操作简便、创伤小、恢复快、可重复进行,对患者身体条件要求不高,具有很高的临床应用价值.

To investigate clinical application of percutaneous lung radiofrequency hyperthermia （PLRH） in non-small cell lung cancer （NSCLC）. Methods： Forty eight patients with NSCLC were treated by PLRH with CT-guided anchor-shaped electrode. Serum CYFRA21-1 was analysed by radioimmunoassay one day before and 10, 20, and 30 days after therapy. Results. Serum CYFRA21-1 was （14.23±8.07）μg·L^-1 in.patients with NSCLC, being （20. 48±11.23） and （5.48±3.42）μg·L^-1 （X±s） in squamous cell carcinoma and adenocarcinoma respectively. Serum CYFRA21-1 after PLRH was not significantly different on day 10 but decreased markedly 30 days after treatment （P〈0. 05）. Conclusions. PLRH treatment of NSCLC is safe, effective, easy to do, with swift recovery, and should be used generally in clinical practice.